Clear answers about capabilities, partnerships and the pharmaceutical ecosystem.

Yes. Jean Vichar evaluates CMO opportunities for products with established formulations and processes, subject to technical, quality, regulatory and commercial fit.

Yes. Depending on the project, support may include formulation and process assessment, technology transfer, scale-up, validation planning, registration-document support and transition to commercial manufacturing.

Jean Vichar directly supports tablets and capsules, metered dose inhalers and nasal sprays. Dry powder inhaler capabilities are provided through Lirok Pharma within the pharmaceutical ecosystem.

Yes. Domestic and international API manufacturers or authorized representatives may introduce relevant products, manufacturing sites and available technical documentation through the API partnership inquiry route.

Aram Pharma is the parent company. It was founded in 1993, building on Dr. Akhavan’s pharmaceutical experience dating to 1965, and focuses on pharmaceutical import, trade and API relationships.

Lirok Pharma provides specialized dry powder inhaler manufacturing. Ti-One supports pharmaceutical distribution, including essential, specialty and super-specialty medicines and related healthcare products under controlled storage and transport practices.

Yes. Transfer programs may include technical-package review, risk and gap assessment, method and process transfer, engineering batches, validation activities and commercial-readiness review.

The first inquiry should not contain confidential formulas, proprietary methods or patient information. A confidentiality agreement and secure exchange method can be arranged before detailed technical information is shared.

Only verified and approved information should be published. Project-specific fit, equipment, capacity and scheduling are confirmed directly during technical evaluation.

No. The website is intended for corporate and business information and does not provide medical, diagnostic or treatment advice.